Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03275103
Registration number
NCT03275103
Ethics application status
Date submitted
5/09/2017
Date registered
7/09/2017
Date last updated
26/06/2024
Titles & IDs
Public title
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Query!
Scientific title
An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma
Query!
Secondary ID [1]
0
0
2018-001041-13
Query!
Secondary ID [2]
0
0
GO39775
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Cevostamab
Treatment: Drugs - Tocilizumab
Experimental: Arm A: Single Step Dose Escalation for Cevostamab - Study drug will be administered intravenously on a 21-day cycle. The step-up dose will be given on Cycle 1 Day 1 and the target dose will be given on C1D8. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
Experimental: Arm B: Double Step Dose Escalation for Cevostamab - In Cycle 1, participants will receive 2 step-up doses and a target dose. The step-up dose will be given on Cycle 1 Day 1 and C1D8. The target dose will be given on C1D15. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
Experimental: Arm C: Single Step Dose Expansion for Cevostamab - The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.
Experimental: Arm D: Double Step Dose Expansion for Cevostamab - The double step dose expansion stage of the study may use the dosing and assessment schedule from the double step dose escalation arm in Cycle 1, based on data from Arm B.
Experimental: Arm E: Expansion Phase for Tocilizumab Pretreatment - All participants will receive a single dose of tocilizumab intravenously. An additional dose of tocilizumab may be instituted as premedication for subsequent Cycle 1 dose(s) of cevostamab and Cycle 1 cevostamab doses for other treatment arms.
Experimental: Arm F: Single Step Dose Expansion for Cevostamab - The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.
Experimental: Arm G: Double Step Dose Expansion for Cevostamab - The double step dose expansion stage of the study may use the dosing and assessment schedule from the double step dose escalation arm in Cycle 1, based on data from Arm B.
Experimental: Arm H: Triple Step Dose Escalation for Cevostamab - In Cycle 1, participants will receive 3 step-up doses and a target dose. The doses will be given on Cycle 1 Days 1, 2-4, 8, and 9-11. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
Experimental: Arm I: Triple Step Dose Expansion for Cevostamab - The triple step dose expansion stage of the study may use the dosing and assessment schedule from the triple step dose escalation arm in Cycle 1, based on data from Arm H.
Experimental: Arm J: Expansion Phase for Tocilizumab Pretreatment - All participants will receive a single dose of tocilizumab intravenously. An additional dose of tocilizumab may be instituted as premedication for subsequent Cycle 1 dose(s) of cevostamab and Cycle 1 cevostamab doses for other treatment arms.
Experimental: Arm K: Compressed Double Step Dose Expansion for Cevostamab - In Cycle 1, participants will receive 2 step-up doses and a target dose. The doses will be given on Cycle 1 Days 1, 4, and 8. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
Treatment: Drugs: Cevostamab
Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.
Treatment: Drugs: Tocilizumab
Tocilizumab will be administered as premedication during Cycle 1.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants with Adverse Events (AEs)
Query!
Assessment method [1]
0
0
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.
Query!
Timepoint [1]
0
0
Up to approximately 8 years
Query!
Primary outcome [2]
0
0
Percentage of Participants With Dose-Limiting Toxicities (DLTs)
Query!
Assessment method [2]
0
0
Dose-Limiting Toxicities (DLTs) will be reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0), except for Cytokine release syndrome (CRS), which will be graded according to the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine Release Syndrome.
Query!
Timepoint [2]
0
0
Up to approximately 8 years
Query!
Primary outcome [3]
0
0
Arms E and J Only: Incidence and Severity of Cytokine-release Syndrome (CRS) Following Tocilizumab Premedication Followed by Treatment with Cevostamab
Query!
Assessment method [3]
0
0
Cytokine release syndrome was recorded as an AE that generally occurs \>30 minutes after the start of Cevostamab administration and at any time afterward in a given cycle.
Query!
Timepoint [3]
0
0
Up to approximately 8 years
Query!
Secondary outcome [1]
0
0
Area Under the Concentration-Time Curve (AUC) of Cevostamab
Query!
Assessment method [1]
0
0
Defined as the total exposure of study drug.
Query!
Timepoint [1]
0
0
Up to approximately 8 years
Query!
Secondary outcome [2]
0
0
AUC of Tocilizumab
Query!
Assessment method [2]
0
0
Defined as the total exposure of study drug.
Query!
Timepoint [2]
0
0
Up to approximately 8 years
Query!
Secondary outcome [3]
0
0
Maximum Observed Serum Concentration (Cmax) of Cevostamab
Query!
Assessment method [3]
0
0
Defined as the maximum observed serum concentration of study drug.
Query!
Timepoint [3]
0
0
Up to approximately 8 years
Query!
Secondary outcome [4]
0
0
Cmax of Tocilizumab
Query!
Assessment method [4]
0
0
Defined as the maximum observed serum concentration of study drug.
Query!
Timepoint [4]
0
0
Up to approximately 8 years
Query!
Secondary outcome [5]
0
0
Minimum Observed Serum Concentration (Cmin) of Cevostamab
Query!
Assessment method [5]
0
0
Defined as the minimum observed serum concentration of study drug.
Query!
Timepoint [5]
0
0
Up to approximately 8 years
Query!
Secondary outcome [6]
0
0
Cmin of Tocilizumab
Query!
Assessment method [6]
0
0
Defined as the minimum observed serum concentration of study drug.
Query!
Timepoint [6]
0
0
Up to approximately 8 years
Query!
Secondary outcome [7]
0
0
Clearance (CL) of Cevostamab
Query!
Assessment method [7]
0
0
Defined as the volume of plasma cleared of the drug per unit time.
Query!
Timepoint [7]
0
0
Up to approximately 8 years
Query!
Secondary outcome [8]
0
0
CL of Tocilizumab
Query!
Assessment method [8]
0
0
Defined as the volume of plasma cleared of the drug per unit time.
Query!
Timepoint [8]
0
0
Up to approximately 8 years
Query!
Secondary outcome [9]
0
0
Volume of Distribution at Steady State (Vdss) of Cevostamab
Query!
Assessment method [9]
0
0
Defined as the actual blood and tissue volume into which a drug is distributed and the relative binding of drug to protein in these spaces.
Query!
Timepoint [9]
0
0
Up to approximately 8 years
Query!
Secondary outcome [10]
0
0
Vdss of Tocilizumab
Query!
Assessment method [10]
0
0
Defined as the actual blood and tissue volume into which a drug is distributed and the relative binding of drug to protein in these spaces.
Query!
Timepoint [10]
0
0
Up to approximately 8 years
Query!
Secondary outcome [11]
0
0
Serum Concentration of Cevostamab
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Up to approximately 8 years
Query!
Secondary outcome [12]
0
0
Serum Concentration of Tocilizumab
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Up to approximately 8 years
Query!
Secondary outcome [13]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [13]
0
0
ORR is defined as percentage of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) .
sCR is defined as CR (as defined below), plus: Normal FLC ratio and absence of clonal cells in bone marrow (BM) by immunohistochemistry (kappa/lambda ratio \</=4:1 or \>/=1:2 for kappa and lambda participants, respectively after counting \>/=100 plasma cells).
CR is defined as no evidence of initial monoclonal protein isotype(s) on immunofixation of the serum and urine, disappearance of any soft tissue plasmacytomas, and \</= 5% plasma cells in BM.
VGPR is defined as Serum and urine M-protein detectable by immunofixation but not on electrophoresis; or \>/=90% reduction in serum M-protein plus urine M-protein level \<100 milligrams (mg)/24 hr.
PR is defined as \>/= 50% reduction of serum M-protein and reduction in 24-hour urine M-protein by \>/= 90% or to \< 200 mg/24 hours.
Query!
Timepoint [13]
0
0
Up to approximately 8 years
Query!
Secondary outcome [14]
0
0
Duration of Response
Query!
Assessment method [14]
0
0
Time from first occurrence of ORR (defined previously) to disease progression (PD) or death from any cause. PD: increase of \>/=25% from lowest response value in one of the following: serum M-protein (absolute increase \>/=0.5 grams per deciliter (g/dL); serum M-protein increase \>/=1g/dL, if lowest M component was \>/=5g/dL; urine M-protein (absolute increase \>/=200 mg/24 hours); no measurable serum and urine M-protein levels: difference between involved and uninvolved free light chain (FLC) levels (absolute increase \>10 mg/dL); no measurable serum and urine M-protein levels and no measurable disease by FLC: BM plasma cell % irrespective of baseline status (absolute % \>/=10%); new lesion(s) \>/=50% increase from lowest point in sum of the products of diameters of \> 1 lesion, or \>/=50% increase in longest diameter of a previous lesion \>1 centimeter (cm) in short axis; \>/=50% increase in circulating plasma cells (minimum 200 cells per microliter) if only measure of disease.
Query!
Timepoint [14]
0
0
Up to approximately 8 years
Query!
Secondary outcome [15]
0
0
Change from Baseline in the Presence Anti-Drug Antibodies (ADAs)
Query!
Assessment method [15]
0
0
To evaluate the immune response to the study drug.
Query!
Timepoint [15]
0
0
Up to approximately 8 years
Query!
Eligibility
Key inclusion criteria
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
* Life expectancy of at least 12 weeks
* Participants must have relapsed or refractory (R/R) multiple myeloma (MM) for which no established therapy for MM is appropriate and available or be intolerant to those established therapies
* Adverse events from prior anti-cancer therapy resolved to Grade < or = 1, except any grade alopecia and/or peripheral sensory or motor neuropathy which must have resolved to Grade < or = 2
* Measurable disease defined by laboratory test results
* Female participants of childbearing age must agree to remain abstinent or use reliable contraceptive methods during the treatment period, and at least 5 months after last dose of study drug. Women must refrain from breastfeeding during the same period.
* Male participants must agree to refrain from donating sperm, to abstain or use a condom during the treatment period, and for at least 2 months after the last dose of tocilizumab (if applicable).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Inability to comply with protocol-mandated hospitalization and activities restrictions
* Pregnant or breastfeeding, or planning to become pregnant during the study or within 5 months after the last dose of cevostamab or within 3 months after the last dose of of tocilizumab (if applicable)
* Prior use of any monoclonal antibody, radioimmunoconjugate, or antibody-drug conjugate as anti-cancer therapy within 4 weeks before first infusion
* Prior treatment with systemic immunotherapeutic agents within 12 weeks or 5 half-lives of the drug, whichever is shorter, before first infusion
* Prior treatment with chimeric antigen receptor (CAR) T-cell therapy within 12 weeks before first cevostamab infusion
* Known treatment-related, immune-mediated adverse events associated with prior immunotherapeutic agents
* Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first cevostamab infusion
* Autologous stem cell transplantation (SCT) within 100 days prior to first infusion
* Prior allogeneic SCT or solid organ transplantation
* Absolute plasma cell count exceeding 500/micro L or 5% of the peripheral blood white cells
* History of autoimmune disease or of confirmed progressive multifocal leukoencephalopathy
* Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)
* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
* Patients with known history of amyloidosis (e.g., positive Congo Red stain or equivalent in tissue biopsy)
* Patients with lesions in proximity of vital organs that may develop sudden decompensation/deterioration in the setting of a tumor flare
* History of other malignancy that could affect compliance with the protocol or interpretation of results
* Current or past history of central nervous system (CNS) disease, or CNS involvement by MM
* Significant cardiovascular disease that may limit a patient's ability to adequately respond to a CRS event
* Symptomatic active pulmonary disease requiring supplemental oxygen
* Within 14 days prior to first cevostamab infusion: known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics within 4 weeks prior to first infusion
* Positive and quantifiable Epstein-Barr virus (EBV) polymerase chain reaction (PCR) or cytomegalovirus (CMV) PCR prior to first study treatment
* Known or suspected chronic active EBV infection, acute or chronic hepatitis C virus (HCV) infection
* Positive serologic or PCR test results for acute or chronic hepatitis B virus (HBV) infection
* Recent major surgery within 4 weeks prior to first infusion
* Human Immunodeficiency Virus (HIV) positive
* Any episode of active, symptomatic COVID-19 infection, or requiring treatment with IV antivirals for COVID-19 (not including COVID-19 primary prophylaxis) within 14 days, prior to first study treatment
* Administration of a live, attenuated vaccine within 4 weeks before first cevostamab infusion or anticipation that such a live attenuated vaccine will be required during the study
* Received systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents), with the exception of corticosteroid treatment <=10 mg/day prednisone or equivalent within 2 weeks prior to first dose of cevostamab and, if applicable, tocilizumab premedication prior to first dose of cevostamab
* History of illicit drug or alcohol abuse within 12 months prior to screening
* Any medical condition or laboratory test abnormality that precludes the participant's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/09/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/12/2025
Query!
Actual
Query!
Sample size
Target
420
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment hospital [2]
0
0
Peter MacCallum Cancer Center - North Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [2]
0
0
3051 - North Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Pennsylvania
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Tennessee
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
Canada
Query!
State/province [10]
0
0
Alberta
Query!
Country [11]
0
0
Canada
Query!
State/province [11]
0
0
Ontario
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Quebec
Query!
Country [13]
0
0
Spain
Query!
State/province [13]
0
0
Navarra
Query!
Country [14]
0
0
Spain
Query!
State/province [14]
0
0
Salamanca
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Genentech, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
Query!
Trial website
https://clinicaltrials.gov/study/NCT03275103
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Genentech, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Reference Study ID Number: GO39775 https://forpatients.roche.com/
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
888-662-6728 (U.S. only)
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/study/NCT03275103
Download to PDF